Ovarian Cancer at Johns Hopkins What's New? Resources Ovarian Cancer Community Coping with Ovarian Cancer Clinical Trials
 



Dr. RJ Kurman

Dr. R Roden

Dr. I-M Shih

Dr. BM Ronnett

Dr. FJ Montz

Dr. DK Armstrong

 
Selected References from Johns Hopkins Clinicians and Researchers
Robert J. Kurman, M.D.
  1. Naora H, Yang YQ, Montz FJ, Seidman JD, Kurman RJ, Roden RB. A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5. (abstract)

  2. Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol. 2001 Apr;25(4):419-32. (abstract)

  3. Kurman RJ, Seidman JD. Ovarian serous borderline tumors: the citadel defended. Hum Pathol 2000 Nov;31(11):1439-40. (no abstract available)

  4. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000 May;31(5):539-57. (abstract)

  5. Kurtz AB, Tsimikas JV, Tempany CM, Hamper UM, Arger PH, Bree RL, Wechsler RJ, Francis IR, Kuhlman JE, Siegelman ES, Mitchell DG, Silverman SG, Brown DL, Sheth S, Coleman BG, Ellis JH, Kurman RJ, Caudry DJ, McNeil BJ. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis--report of the Radiology Diagnostic Oncology Group. Radiology 1999 Jul;212(1):19-27. (abstract)

  6. Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 1999 Jun;23(6):617-35. (abstract)

  7. Sherman ME, Lee JS, Burks RT, Struewing JP, Kurman RJ, Hartge P. Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis. Int J Gynecol Pathol 1999 Apr;18(2):151-7. (abstract)

  8. Seidman JD, Sherman ME, Kurman RJ. Recurrent serous borderline tumors of the ovary. Int J Gynecol Pathol 1998 Oct;17(4):387-9. (no abstract available)

  9. Katabuchi H, Tashiro H, Cho KR, Kurman RJ, Hedrick Ellenson L. Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53. Int J Gynecol Pathol 1998 Jan;17(1):54-60. (abstract)

  10. Riopel MA, Perlman EJ, Seidman JD, Kurman RJ, Sherman ME. Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcemic small cell carcinomas. Int J Gynecol Pathol 1998 Jan;17(1):46-53. (abstract)

  11. Ronnett BM, Shmookler BM, Diener-West M, Sugarbaker PH, Kurman RJ. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 1997 Jan;16(1):1-9. (abstract)

  12. Ronnett BM, Shmookler BM, Sugarbaker PH, Kurman RJ. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 1997;2:197-226. (abstract)

  13. Ronnett BM, Kurman RJ, Shmookler BM, Sugarbaker PH, Young RH. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol 1997 Oct;21(10):1144-55. (abstract)

  14. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996 Nov;20(11):1331-45. (abstract)

  15. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996 Nov;20(11):1319-30. (abstract)

  16. Silva EG, Kurman RJ, Russell P, Scully RE. Symposium: ovarian tumors of borderline malignancy. Int J Gynecol Pathol 1996 Oct;15(4):281-302. (no abstract available)

  17. Ronnett BM, Kurman RJ, Zahn CM, Shmookler BM, Jablonski KA, Kass ME, Sugarbaker PH. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol 1995 May;26(5):509-24. (abstract)

  18. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 1995 Dec;19(12):1390-408. (abstract)

  19. Barnhill DR, Kurman RJ, Brady MF, Omura GA, Yordan E, Given FT, Kucera PR, Roman LD. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 1995 Nov;13(11):2752-6. (abstract)

  20. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993 Apr;12(2):120-7. (abstract)

  21. Tyler CW, Lee NC, Robboy SJ, Kurman RJ, Paris AL, Wingo PA, Williamson GD. The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists? Am J Obstet Gynecol 1991 Jan;164(1 Pt 1):65-70. (abstract)

  22. Tracy SL, Askin FB, Reddick RL, Jackson B, Kurman RJ. Progesterone secreting Sertoli cell tumor of the ovary. Gynecol Oncol 1985 Sep;22(1):85-96. (abstract)

  23. Huang SC, Chen HC, Kurman RJ, Yang YS, Wen HK, Hsieh CY, Wei PY, How SW, hen TY, Ouyang PC. Secretion of human chorionic gonadotropin and alpha-fetoprotein by an varian germ cell tumor of apparent yolk sac origin. Gynecol Oncol 1984 Jun;18(2):240-6. (abstract)

  24. Kurman RJ. Contributions of immunocytochemistry to gynaecological pathology. Clin Obstet Gynaecol 1984 Apr;11(1):5-23. (abstract)

  25. Kurman RJ, Ganjei P, Nadji M. Contributions of immunocytochemistry to the diagnosis and study of ovarian neoplasms. Int J Gynecol Pathol 1984;3(1):3-26. (no abstract available)

  26. Zaloudek C, Kurman RJ. Recent advances in the pathology of ovarian cancer. Clin Obstet Gynaecol 1983 Aug;10(2):155-85. (no abstract available)



Brigitte M. Ronnett, M.D.
  1. Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 1999 Jun;23(6):617-35. (abstract)

  2. Szych C, Staebler A, Connolly DC, Wu R, Cho KR, Ronnett BM. Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol 1999 Jun;154(6):1849-55. (abstract)

  3. Ronnett BM, Shmookler BM, Diener-West M, Sugarbaker PH, Kurman RJ. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 1997 Jan;16(1):1-9. (abstract)

  4. Ronnett BM, Shmookler BM, Sugarbaker PH, Kurman RJ. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 1997;2:197-226. (abstract)

  5. Ronnett BM, Kurman RJ, Shmookler BM, Sugarbaker PH, Young RH. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol 1997 Oct;21(10):1144-55. (abstract)

  6. Ronnett BM, Kurman RJ, Zahn CM, Shmookler BM, Jablonski KA, Kass ME, Sugarbaker PH. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol 1995 May;26(5):509-24. (abstract)

  7. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 1995 Dec;19(12):1390-408. (abstract)


Richard Roden, Ph.D.
  1. Naora H, Yang YQ, Montz FJ, Seidman JD, Kurman RJ, Roden RB. A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5. (abstract)

  2. Naora H, Montz FJ, Chai CY, Roden RB. Aberrant expression of homeobox gene HOXA7 is associated with mullerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response. Proc Natl Acad Sci U S A 98:15209-14, 2001. (abstract)

  3. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Ling M, Slater LA, Roden RB, Wu TC. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther 12:235-52, 2001. (abstract)

  4. Ling M, Kanayama M, Roden R, Wu TC. Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J Biomed Sci. 2000 Sep-Oct;7(5):341-56. (abstract)


Ie-ming Shih, Ph.D.
  1. Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll LJ, Montz FJ, Roden R, Zhang Z, Chan DW, Kurman RJ, Shih IeM. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst. 2002 Nov 20;94(22):1697-703. (abstract)

  2. Chang HW, Ali SZ, Cho SK, Kurman RJ, Shih IeM. Detection of allelic imbalance in ascitic supernatant by digital single nucleotide polymorphism analysis. Clin Cancer Res 2002 Aug;8(8):2580-5 (abstract)

  3. Singer G, Kurman RJ, Chang HW, Cho SK, Shih IeM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002 Apr;160(4):1223-8 (abstract)


F. J. Montz, M.D.
  1. Naora H, Yang YQ, Montz FJ, Seidman JD, Kurman RJ, Roden RB. A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5. (abstract)

  2. Bristow RE, Smith Sehdev AE, Kaufman HS, Montz FJ. Ablation of metastatic ovarian carcinoma with the argon beam coagulator: pathologic analysis of tumor destruction. Gynecol Oncol. 2001 Oct;83(1):49-55. (abstract)

  3. Bristow RE, Montz FJ. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol. 2001 Oct;83(1):39-48. (abstract)

  4. Bristow RE, Montz FJ. Leiomyomatosis peritonealis disseminata and ovarian Brenner tumor associated with tamoxifen use. Int J Gynecol Cancer. 2001 Jul-Aug;11(4):312-5. (abstract)

  5. Lambrou NC, Buller JL, Thompson JR, Cundiff GW, Chou B, Montz FJ. Prevalence of perioperative complications among women undergoing reconstructive pelvic surgery. Am J Obstet Gynecol 2000 Dec;183(6):1355-60. (abstract)

  6. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, Morin PJ. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000 Nov 15;60(22):6281-7. (abstract)

  7. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, Montz FJ. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000 Oct 1;89(7):1532-40. (abstract)

  8. Dardik RB, Dardik M, Westra W, Montz FJ. Malignant struma ovarii: two case reports and a review of the literature. Gynecol Oncol 1999 Jun;73(3):447-51. (abstract)

  9. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999 Mar;72(3):278-87. (abstract)

  10. Holschneider CH, Johnson MT, Knox RM, Rezai A, Ryan WJ, Montz FJ. Bullatacin--in vivo and in vitro experience in an ovarian cancer model. Cancer Chemother Pharmacol 1994;34(2):166-70. (abstract)

  11. Montz FJ, Monk BJ, Lacy SM. The Gore-Tex Surgical Membrane: effectiveness as a barrier to inhibit postradical pelvic surgery adhesions in a porcine model. Gynecol Oncol 1992 Jun;45(3):290-3. (abstract)

  12. Berek JS, Welander C, Schink JC, Grossberg H, Montz FJ, Zigelboim J. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol 1991 Mar;40(3):237-43. (abstract)



Deb K. Armstrong, M.D.
  1. O'Reilly S, Fleming GF, Barker SD, Walczak JR, Bookman MA, McGuire WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol 1997 Jan;15(1):177-86. (abstract)

  2. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989 Aug 15;111(4):273-9. (abstract)


  
     
HONcode Logo We subscribe to the HONcode principles. Verify

Copyright © 2000-2017 Johns Hopkins University.
All rights reserved.
Disclaimer & Privacy   Last modified December 02, 2002